CD8A and neoplasm: Notably, research conducted by Roger Esteban-Fabró et al. revealed that cabozantinib therapy significantly reduces the population of CD8+PD-1+ T cells within the tumor microenvironment while increasing the infiltration of neutrophils, thus enhancing therapeutic efficacy for patients with HCC 34.